Value
2.8/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 2.4 |
| Analyst target | 3.0 |
- ▸Expensive valuation
ADPT · Why this verdict
Why Adaptive Biotechnologies Corpor (ADPT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Return on equity, return on assets, operating margin, and net margin all score near zero, placing overall business quality well below the minimum threshold the strategy requires; free cash flow exists but margins are thin at 5%, and no competitive moat has been identified. Quality breakdown | Operating margin turns positive on a trailing twelve-month basis within the next four quarters for this pillar to lose its force. | →Stable |
| CounterInvesting-phase companies with durable technology platforms routinely carry near-zero margins while establishing market position; the free-cash-flow-positive status at this stage is already a meaningful milestone relative to earlier-stage peers. | ||
Revenue grew 35% year-over-year, placing the company at the top of its peer group on growth metrics and confirming meaningful commercial traction for its core diagnostic offering. Growth breakdown | Revenue growth remains at or above 20% year-over-year for the next two reported quarters. | →Stable |
| CounterHigh growth from a small base can decelerate sharply once early-adopter penetration saturates; without widening gross margins and meaningful operating leverage, growth that does not convert into cash has limited value for equity holders. | ||
The business is exposed to two high-severity concentration risks flagged in its public filings: dependence on a single commercial product and reliance on a single supplier for sequencing infrastructure, leaving revenue vulnerable to disruption on either front. Risk breakdown | The company publicly announces either a second revenue-generating product or a second validated supplier relationship within 12 months. | →Stable |
| CounterDeep specialization in a single high-value diagnostic application may reflect intentional platform focus rather than fragility; market leadership in one indication can generate durable pricing power that diversified competitors cannot match. | ||
The company beat earnings estimates in all four of the past four quarters with an average positive surprise exceeding 60%, yet the stock sits just below its analyst-derived upside target with only 0.4% headroom remaining — meaning the beat cadence appears already priced in and the reward-to-risk ratio is essentially flat. Earnings | Upside to the analyst price target expands beyond 10% — implying either a target revision upward or a pullback in the stock price — before the setup justifies fresh positioning. | →Stable |
| CounterA consistent pattern of beating estimates by wide margins signals management may be consistently under-promising; if the next estimate revision cycle raises the consensus target materially, the current proximity to target would represent a favorable entry rather than a ceiling. | ||
Return on equity, return on assets, operating margin, and net margin all score near zero, placing overall business quality well below the minimum threshold the strategy requires; free cash flow exists but margins are thin at 5%, and no competitive moat has been identified.
→StableQuality breakdown
- Expectation
- Operating margin turns positive on a trailing twelve-month basis within the next four quarters for this pillar to lose its force.
CounterInvesting-phase companies with durable technology platforms routinely carry near-zero margins while establishing market position; the free-cash-flow-positive status at this stage is already a meaningful milestone relative to earlier-stage peers.
Revenue grew 35% year-over-year, placing the company at the top of its peer group on growth metrics and confirming meaningful commercial traction for its core diagnostic offering.
→StableGrowth breakdown
- Expectation
- Revenue growth remains at or above 20% year-over-year for the next two reported quarters.
CounterHigh growth from a small base can decelerate sharply once early-adopter penetration saturates; without widening gross margins and meaningful operating leverage, growth that does not convert into cash has limited value for equity holders.
The business is exposed to two high-severity concentration risks flagged in its public filings: dependence on a single commercial product and reliance on a single supplier for sequencing infrastructure, leaving revenue vulnerable to disruption on either front.
→StableRisk breakdown
- Expectation
- The company publicly announces either a second revenue-generating product or a second validated supplier relationship within 12 months.
CounterDeep specialization in a single high-value diagnostic application may reflect intentional platform focus rather than fragility; market leadership in one indication can generate durable pricing power that diversified competitors cannot match.
The company beat earnings estimates in all four of the past four quarters with an average positive surprise exceeding 60%, yet the stock sits just below its analyst-derived upside target with only 0.4% headroom remaining — meaning the beat cadence appears already priced in and the reward-to-risk ratio is essentially flat.
→StableEarnings
- Expectation
- Upside to the analyst price target expands beyond 10% — implying either a target revision upward or a pullback in the stock price — before the setup justifies fresh positioning.
CounterA consistent pattern of beating estimates by wide margins signals management may be consistently under-promising; if the next estimate revision cycle raises the consensus target materially, the current proximity to target would represent a favorable entry rather than a ceiling.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Adaptive Biotechnologies is a diagnostics-stage company with strong revenue growth and a perfect four-quarter earnings beat streak, but the business has not yet achieved meaningful profitability, the stock trades essentially at its upside target leaving almost no reward for the risk taken, and concentrated dependence on a single product and a single supplier create asymmetric downside that the thin margin does not justify.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 4.7 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 9.6 |
| FCF quality | 4.1 |
| Moat | 5.0 |
| Piotroski F | 4.4 |
- ▸FCF-positive but moderate margins (FCF margin 5%, FCF yield 0.5%)
- ▸No competitive moat
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 35% YoY
Momentum
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 2.1 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 8.5 |
| Analyst rating | 7.7 |
| Price target | 4.4 |
- ▸LLM news sentiment: +0.70 (n=1)
- ▸Light analyst coverage (7.0) — signal dampened
Insider
3.4/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Notable insider selling — $9,784,815 (0.289% of mkt cap)
Peer rank
2.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.9 |
| quality rank | 1.3 |
| growth rank | 8.1 |
- ▸Industry growth leader
Technical
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.7 |
| support resistance | 2.3 |
| 52w position | 8.6 |
Risk (lower is worse)
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.0 |
| days to cover | 7.3 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 3.1 |
| debt equity | 5.4 |
- ▸High IV: 121%
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 5.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:7.2>=5.5
- 8K:CLEAN
- NEWS_BOOST:ANALYST:0.70
- EARNINGS_PROXIMITY:32d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-1.1=NEGATIVE
Warning (1)
- INSIDER:0.29%=MODERATE
Reward-to-Risk
-1.11
Upside
-16.7%
Downside
15.0%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 63, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — Beta 2.07>1.3, MCap $3.4B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:-1.1=NEGATIVE.
The strongest dimensions are Growth at 10.0, Momentum at 7.2, and Sentiment at 7.0; the weakest are Peer rank at 2.8, Value at 2.8, and Quality at 3.1. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -1.11 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Strong Revenue Growth Leadership
Trip ifRevenue growth falls below 20% year-over-year for 2 consecutive quarters.
- P2Single Product Supplier Concentration
Trip ifThe company discloses a second sequencing supplier or a second commercial product generating more than $5M in quarterly revenue.
- P3Below Floor Profitability Quality
Trip ifOperating margin rises above 0% on a trailing-twelve-month basis.
- P4Beats Priced In No Upside
Trip ifUpside to the analyst price target expands beyond 10%, implying a consensus target revision above $19.25.